BioScrip Company Profile (NASDAQ:BIOS)

About BioScrip (NASDAQ:BIOS)

BioScrip logoBioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient's physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient's specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Hospitals, Clinics & Primary Care Services
  • Sub-Industry: Health Care Services
  • Symbol: NASDAQ:BIOS
  • CUSIP: 09069N10
  • Web:
  • Market Cap: $331.43 million
  • Outstanding Shares: 127,475,000
Average Prices:
  • 50 Day Moving Avg: $2.75
  • 200 Day Moving Avg: $2.38
  • 52 Week Range: $0.98 - $3.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.29
  • P/E Growth: -0.48
Sales & Book Value:
  • Annual Revenue: $900.58 million
  • Price / Sales: 0.37
  • Book Value: ($0.50) per share
  • Price / Book: -5.20
  • EBITDA: $25.07 million
  • Net Margins: -8.03%
  • Return on Assets: -7.39%
  • Debt-to-Equity Ratio: -7.49%
  • Current Ratio: 1.85%
  • Quick Ratio: 1.57%
  • Average Volume: 1.41 million shs.
  • Beta: 0.24
  • Short Ratio: 21.49

Frequently Asked Questions for BioScrip (NASDAQ:BIOS)

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip, Inc. (NASDAQ:BIOS) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.01. The company earned $218.11 million during the quarter, compared to analysts' expectations of $220.05 million. The business's revenue for the quarter was down 6.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.14) EPS. View BioScrip's Earnings History.

When will BioScrip make its next earnings announcement?

BioScrip is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for BioScrip.

Where is BioScrip's stock going? Where will BioScrip's stock price be in 2017?

4 brokers have issued 12-month price objectives for BioScrip's shares. Their predictions range from $3.50 to $4.50. On average, they expect BioScrip's share price to reach $3.94 in the next twelve months. View Analyst Ratings for BioScrip.

What are analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:

  • 1. According to Zacks Investment Research, "BioScrip exited the second quarter on a dismal note with revenues missing the Zacks Consensus Estimate and adjusted net loss wider-than-expected. Management’s unimpressive 2017 guidance, which includes the negative impact of the Cures Act legislation, also adds to our concerns. Nonetheless, the market is upbeat about BioScrip’s announcement to continue to offer certain core product lines to UnitedHealthcare. We are encouraged by the company’s recent progress, courtesy of its new multi-faceted CORE plan which was adopted to improve the financial position. Further, the company achieved annualized supply chain improvement of roughly $20 million since the acquisition of Home Solutions. Over the last three months, BioScrip has been trading above the broader industry." (8/14/2017)
  • 2. Jefferies Group LLC analysts commented, "We are incrementally more positive on BIOS following better-than-expected 4Q results. Growth in Core revenues is progressing according to plan & expense initiatives should offset a majority of the headwind from the 21st Century Cures Act. Accelerating EBITDA growth throughout 2017 should provide investors with increasing confidence in BIOS ability to reduce debt leverage to more normalized levels (~6x) by YE17 & put BIOS on a path to >$80MM of EBITDA in 2018." (3/6/2017)

Are investors shorting BioScrip?

BioScrip saw a decline in short interest in the month of September. As of September 29th, there was short interest totalling 13,005,531 shares, a decline of 19.6% from the September 15th total of 16,176,982 shares. Based on an average daily volume of 982,156 shares, the short-interest ratio is presently 13.2 days. Currently, 10.3% of the company's shares are short sold.

Who are some of BioScrip's key competitors?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:

  • Daniel E. Greenleaf, President, Chief Executive Officer, Director
  • Stephen M. Deitsch, Chief Financial Officer, Senior Vice President, Treasurer
  • David Evans, Chief Operating Officer, Senior Vice President
  • Betty Y Jang, Senior Vice President, Chief Compliance Officer
  • Kathryn M. Stalmack, General Counsel
  • Scott J. Davido, Chief Implementation Officer
  • Michael G. Bronfein CPA, Director
  • Steven Neumann, Director
  • Christopher S. Shackelton, Director
  • David W. Golding, Independent Director

Who owns BioScrip stock?

BioScrip's stock is owned by a variety of of retail and institutional investors. Top institutional investors include COLISEUM CAPITAL MANAGEMENT, LLC (16.50%), COLISEUM CAPITAL MANAGEMENT, LLC (14.60%) and GAMCO INVESTORS, INC. ET AL (9.19%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, Michael G Bronfein and R Carter Pate. View Institutional Ownership Trends for BioScrip.

How do I buy BioScrip stock?

Shares of BioScrip can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BioScrip stock can currently be purchased for approximately $2.60.

MarketBeat Community Rating for BioScrip (NASDAQ BIOS)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioScrip (NASDAQ:BIOS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.94 (51.44% upside)
Consensus Price Target History for BioScrip (NASDAQ:BIOS)
Price Target History for BioScrip (NASDAQ:BIOS)
Analysts' Ratings History for BioScrip (NASDAQ:BIOS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017SunTrust Banks, Inc.UpgradeHold -> Buy$3.25 -> $3.75HighView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingBuy$3.00 -> $4.00HighView Rating Details
6/26/2017Barrington ResearchBoost Price TargetOutperform$3.50HighView Rating Details
1/3/2017Lake Street CapitalInitiated CoverageBuy$4.50N/AView Rating Details
3/5/2016StephensReiterated RatingBuyN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for BioScrip (NASDAQ:BIOS)
Earnings by Quarter for BioScrip (NASDAQ:BIOS)
Earnings History by Quarter for BioScrip (NASDAQ BIOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.10)N/AView Earnings Details
8/8/2017Q2 2017($0.10)($0.11)$220.05 million$218.11 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.12)($0.16)$230.23 million$217.80 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.08)($0.08)$236.67 million$240.10 millionViewListenView Earnings Details
11/7/2016Q3($0.05)($0.12)$223.26 million$224.50 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.08)$229.58 million$232.50 millionViewListenView Earnings Details
5/5/2016Q1($0.12)($0.17)$232.38 million$238.50 millionViewListenView Earnings Details
3/2/2016Q4($0.08)($0.13)$238.30 million$243.75 millionViewListenView Earnings Details
11/4/2015Q315($0.10)($0.19)$229.89 million$247.20 millionViewListenView Earnings Details
8/10/2015Q215($0.11)($0.02)$269.38 million$262.40 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.19)$259.60 million$261.70 millionViewListenView Earnings Details
3/2/2015Q414($0.02)($0.72)$259.62 million$253.70 millionViewListenView Earnings Details
11/5/2014Q314$0.02($0.45)$240.08 million$244.00 millionViewListenView Earnings Details
8/6/2014Q214($0.05)($0.10)$233.70 million$247.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.17)$222.65 million$239.60 millionViewListenView Earnings Details
2/26/2014Q413$0.02$0.02$237.58 million$243.50 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.04$0.13$206.47 million$190.73 millionViewListenView Earnings Details
5/8/2013Q1 2013$0.02$0.04$189.36 million$199.07 millionViewListenView Earnings Details
3/11/2013Q4 2012$0.01$0.04$173.87 million$180.70 millionViewListenView Earnings Details
11/7/2012Q312($0.01)($0.01)$159.86 million$170.36 millionViewN/AView Earnings Details
8/8/2012($0.01)($0.07)ViewN/AView Earnings Details
5/9/2012($0.01)($0.05)ViewN/AView Earnings Details
3/9/2012$0.09$0.12ViewN/AView Earnings Details
11/8/2011$0.09$0.10ViewN/AView Earnings Details
8/8/2011$0.08$0.10ViewN/AView Earnings Details
5/3/2011($0.01)$0.05ViewN/AView Earnings Details
3/11/2011$0.04($1.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioScrip (NASDAQ:BIOS)
2017 EPS Consensus Estimate: ($0.27)
2018 EPS Consensus Estimate: ($0.23)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.14)($0.08)($0.12)
Q2 20172($0.10)($0.06)($0.08)
Q3 20173($0.08)($0.04)($0.06)
Q4 20173($0.03)$0.00($0.02)
Q1 20181($0.10)($0.10)($0.10)
Q2 20181($0.07)($0.07)($0.07)
Q3 20181($0.06)($0.06)($0.06)
Q4 20181$0.00$0.00$0.00
(Data provided by Zacks Investment Research)


Dividend History for BioScrip (NASDAQ:BIOS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioScrip (NASDAQ:BIOS)
Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 84.77%
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Michael G BronfeinDirectorSell27,000$2.69$72,630.00View SEC Filing  
9/7/2017Coliseum Capital Management, LDirectorSell2,846,941$2.93$8,341,537.13View SEC Filing  
8/17/2017Coliseum Capital Management, LDirectorSell886,478$3.08$2,730,352.24View SEC Filing  
11/11/2016Jeffrey M KregerCFOBuy10,000$1.32$13,200.00View SEC Filing  
11/10/2016Daniel E GreenleafCEOBuy16,000$1.30$20,800.00View SEC Filing  
11/10/2016R Carter PateDirectorBuy20,000$1.30$26,000.00View SEC Filing  
6/22/2016Coliseum Capital Management, LDirectorBuy4,200,000$2.00$8,400,000.00View SEC Filing  
6/17/2016David W GoldingDirectorBuy12,500$2.48$31,000.00View SEC Filing  
8/24/2015Coliseum Capital Management, LDirectorBuy789,503$1.88$1,484,265.64View SEC Filing  
8/21/2015Coliseum Capital Management, LDirectorBuy632,907$1.81$1,145,561.67View SEC Filing  
8/18/2015David W GoldingDirectorBuy20,000$1.54$30,800.00View SEC Filing  
3/16/2015Richard M SmithCEOBuy5,000$4.27$21,350.00View SEC Filing  
3/12/2015Yon JordenDirectorBuy5,000$3.47$17,350.00View SEC Filing  
6/16/2014Myron Z HolubiakDirectorSell5,000$7.94$39,700.00View SEC Filing  
5/14/2014Yon JordenDirectorBuy5,000$7.21$36,050.00View SEC Filing  
8/30/2013Daniel ColucciVPSell18,500$12.40$229,400.00View SEC Filing  
8/28/2013David HubersDirectorSell11,200$12.23$136,976.00View SEC Filing  
8/28/2013Patricia BoguszVPSell39,687$11.94$473,862.78View SEC Filing  
8/19/2013Kohlberg Management V, LlcInsiderSell6,895,873$13.00$89,646,349.00View SEC Filing  
7/19/2013Myron Z HolubiakDirectorSell31,200$16.34$509,808.00View SEC Filing  
11/13/2012Stuart A SamuelsDirectorSell11,200$9.66$108,192.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioScrip (NASDAQ:BIOS)
Latest Headlines for BioScrip (NASDAQ:BIOS)
DateHeadline logoBioScrip to Host Third Quarter Results Call - GlobeNewswire (press release) - October 17 at 5:23 PM logoBioScrip to Host Third Quarter Results Call - October 16 at 5:20 PM logoBioScrip, Inc. (BIOS) Receives Consensus Rating of "Hold" from Brokerages - October 15 at 4:46 AM logoETFs with exposure to BioScrip, Inc. : October 13, 2017 - October 13 at 5:12 PM logoBioScrip Inc (BIOS) Sees Large Decline in Short Interest - October 13 at 1:32 AM logoFive ways technology could make health care very personal - October 12 at 5:24 PM logo Brokerages Expect BioScrip, Inc. (BIOS) Will Announce Earnings of -$0.10 Per Share - October 7 at 8:24 PM logoBioScrip Announces Availability of ALS Home Infusion Therapy ... - GlobeNewswire (press release) - October 5 at 3:29 PM logoBioScrip Announces Availability of ALS Home Infusion Therapy - October 5 at 3:29 PM logoBioScrip, Inc. breached its 50 day moving average in a Bullish Manner : BIOS-US : October 3, 2017 - October 3 at 4:21 PM logoBioScrip, Inc. :BIOS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 - October 2 at 12:47 PM logoContrasting Premier (PINC) and BioScrip (BIOS) - September 27 at 2:12 PM logo$203.04 Million in Sales Expected for BioScrip, Inc. (BIOS) This Quarter - September 21 at 11:58 AM logoPremier (PINC) & BioScrip (BIOS) Financial Contrast - September 21 at 12:22 AM logoBioScrip, Inc. (BIOS) Given Average Rating of "Hold" by Analysts - September 20 at 4:44 AM logoBioScrip, Inc. (BIOS) Director Sells $72,630.00 in Stock - September 19 at 4:28 PM logo Brokerages Expect BioScrip, Inc. (BIOS) to Announce -$0.10 Earnings Per Share - September 19 at 2:18 AM logoHead to Head Survey: AMN Healthcare Services (AMN) and BioScrip (BIOS) - September 17 at 6:38 PM logoBioScrip, Inc. (BIOS) Sees Significant Decline in Short Interest - September 15 at 1:28 AM logoHealthways (TVTY) vs. BioScrip (BIOS) Head-To-Head Analysis - September 12 at 10:24 PM logoBioScrip: Cost Cuts and Potential Legislation Sparks Analyst Coverage - September 12 at 4:50 PM logoBRIEF-Coliseum Capital reports 14.6 pct stake in Bioscrip - September 8 at 4:57 PM logoBioScrip, Inc. (BIOS) Director Sells $8,341,537.13 in Stock - September 7 at 10:22 PM logoAMN Healthcare Services (AMN) & BioScrip (BIOS) Critical Comparison - September 6 at 12:16 AM logoBioScrip, Inc. (BIOS) Expected to Announce Quarterly Sales of $203.04 Million - September 2 at 8:06 AM logoBioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised) - September 1 at 4:53 PM logoHealthways (TVTY) & BioScrip (BIOS) Financial Contrast - September 1 at 6:06 AM logoBioScrip, Inc. – Value Analysis (NASDAQ:BIOS) : August 30, 2017 - August 30 at 2:59 AM logoReviewing BioScrip (BIOS) and AMN Healthcare Services (AMN) - August 27 at 2:28 AM logoBioScrip, Inc. (BIOS) Receives Average Rating of "Hold" from Brokerages - August 26 at 4:12 AM
News IconUS Bioservices to resolve kickback claims for $13.4 mln -filing ... - Business Insider - August 24 at 2:49 AM logoBioScrip, Inc. breached its 50 day moving average in a Bearish Manner : BIOS-US : August 23, 2017 - August 23 at 4:43 PM logoBioScrip's Infusion Business Strong, Dull 2017 View a Drag - August 21 at 9:33 PM logoBioScrip's Infusion Business Strong, Dull 2017 View a Drag - Nasdaq - August 21 at 4:30 PM logoColiseum Capital Management, L Sells 886,478 Shares of BioScrip, Inc. (BIOS) Stock - August 17 at 10:27 PM logo$205.29 Million in Sales Expected for BioScrip, Inc. (BIOS) This Quarter - August 15 at 3:28 PM logoFY2017 EPS Estimates for BioScrip, Inc. Increased by Analyst (NASDAQ:BIOS) - August 14 at 5:52 AM logoBarrington Research Equities Analysts Boost Earnings Estimates for BioScrip, Inc. (NASDAQ:BIOS) - August 14 at 3:36 AM logoBioScrip (BIOS) Shows Strength: Stock Adds 6.6% in Session - August 11 at 5:00 PM logoBioScrip, Inc. (NASDAQ:BIOS) Receives Buy Rating from Jefferies Group LLC - August 10 at 2:16 PM logoBioScrip, Inc. (BIOS) Releases Earnings Results, Misses Expectations By $0.01 EPS - August 9 at 10:05 PM logoBioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss - August 9 at 4:46 PM logoEdited Transcript of BIOS earnings conference call or presentation 8-Aug-17 1:00pm GMT - August 9 at 2:42 AM logoBioScrip Reports Second Quarter 2017 Financial Results Nasdaq ... - GlobeNewswire (press release) - August 8 at 4:20 PM logoBRIEF-BioScrip qtrly loss per share $0.26 - Reuters - August 8 at 4:20 PM logoBioScrip Reports Second Quarter 2017 Financial Results - August 8 at 4:20 PM logoBioScrip reports 2Q loss - August 8 at 4:20 PM logoBioScrip, Inc. -- Moody's rates BioScrip's new debt; Caa2 CFR affirmed - August 1 at 5:25 PM logoBioScrip, Inc. (BIOS) Receives Average Rating of "Buy" from Analysts - August 1 at 9:23 AM logoBioScrip, Inc. (BIOS) Scheduled to Post Quarterly Earnings on Monday - July 31 at 8:11 AM



BioScrip (BIOS) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.